Sage Therapeutics, Inc. (NASDAQ:SAGE - Get Free Report) has been given an average rating of "Reduce" by the fifteen research firms that are covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell recommendation and fourteen have given a hold recommendation to the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $8.02.

• 5 Biotech stocks tapping into unmet mental health treatment needs

A number of research analysts have recently issued reports on the stock. Needham & Company LLC restated a "hold" rating on shares of Sage Therapeutics in a research report on Monday, June 16th. Truist Financial set a $9.00 target price on shares of Sage Therapeutics and gave the stock a "hold" rating in a report on Tuesday, June 17th. Wall Street Zen lowered Sage Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday, June 7th. Scotiabank cut Sage Therapeutics from a "strong-buy" rating to a "hold" rating and dropped their price target for the stock from $12.00 to $9.20 in a research report on Tuesday, July 8th. Finally, Canaccord Genuity Group boosted their price objective on Sage Therapeutics from $8.00 to $8.50 and gave the company a "hold" rating in a research report on Tuesday, June 17th.

Check Out Our Latest Stock Analysis on Sage Therapeutics

Sage Therapeutics Price Performance

SAGE opened at $8.68 on Thursday. Sage Therapeutics has a 12-month low of $4.62 and a 12-month high of $11.44. The stock has a market capitalization of $543.54 million, a PE ratio of -1.50 and a beta of 0.29. The firm's fifty day moving average price is $8.25 and its 200 day moving average price is $7.65.

Sage Therapeutics (NASDAQ:SAGE - Get Free Report) last issued its earnings results on Wednesday, July 30th. The biopharmaceutical company reported ($0.79) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.96) by $0.17. Sage Therapeutics had a negative net margin of 747.63% and a negative return on equity of 68.99%. The business had revenue of $31.66 million for the quarter, compared to analyst estimates of $16.69 million. During the same quarter in the prior year, the business posted ($1.70) EPS. The company's revenue for the quarter was up 266.0% on a year-over-year basis. On average, equities research analysts forecast that Sage Therapeutics will post -3.52 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Sage Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the business. Teacher Retirement System of Texas boosted its position in Sage Therapeutics by 21.6% during the fourth quarter. Teacher Retirement System of Texas now owns 13,768 shares of the biopharmaceutical company's stock worth $75,000 after purchasing an additional 2,446 shares during the period. AlphaQuest LLC acquired a new stake in shares of Sage Therapeutics in the first quarter worth $32,000. ProShare Advisors LLC boosted its holdings in shares of Sage Therapeutics by 31.2% during the 4th quarter. ProShare Advisors LLC now owns 18,281 shares of the biopharmaceutical company's stock worth $99,000 after buying an additional 4,350 shares during the period. Invesco Ltd. grew its stake in Sage Therapeutics by 5.3% in the 4th quarter. Invesco Ltd. now owns 92,528 shares of the biopharmaceutical company's stock valued at $502,000 after buying an additional 4,629 shares during the last quarter. Finally, Headlands Technologies LLC acquired a new position in Sage Therapeutics in the 1st quarter valued at $37,000. Institutional investors and hedge funds own 99.22% of the company's stock.

About Sage Therapeutics

(Get Free Report

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.

See Also

• Five stocks we like better than Sage Therapeutics
• What Are Dividend Achievers? An Introduction
• Visa Beats Q3 Earnings Expectations, So Why Did the Market Panic?
• What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
• How Marvell Went From Short Target to Breakout Star
• How to start investing in penny stocks
• Palo Alto Networks: The All‑in‑One Cybersecurity Powerhouse

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Sage Therapeutics Right Now?

Before you consider Sage Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sage Therapeutics wasn't on the list.

While Sage Therapeutics currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here